November 22, 2005

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Revisions to Communicable Disease Control Manual, Chapter 2 – Immunization Program

Please note the following changes to the Communicable Disease Control Manual, Chapter 2 – Immunization Program:

(1) Section VII – Biological Products

Page 4: [Diphtheria-Tetanus-Polio Adsorbed (DT/IPV) Code Name: Glen™]:
• This product has been discontinued. Previous page 4a (Dukoral™) now page 4.

Pages 7, 8, 9, 9a, and 10 (Hepatitis A vaccines):
• Amended footnotes to include ViVAXIM™ in the list of interchangeable hepatitis A vaccines.

Pages 16, 18, 20 and 22 (Hepatitis B vaccines):
• Premature infants weighing < 2000 grams requiring a birth dose of Hepatitis B vaccine (when mother is HBsAg positive, when mother is at high risk and infectious status is unknown, or when the infant has another caregiver or a household contact with chronic hepatitis B) will need a four dose series of vaccine, with a 0 – 1 – 6 – 8 month schedule.

Pages 24 and 25 (Twinrix™ and Twinrix Junior™ vaccines):
• An anaphylactic reaction to yeast is a contraindication for Twinrix™ and Twinrix Junior™ vaccines.

Administrative Circular # 2005:16
Page 32b (INFLUVAC™):
- New page for this recently licensed influenza vaccine.

Page 34 (MMR vaccine):
- Under “Contraindications”, wording now consistent with guideline in Section III – Contraindications and Routine Precautions for Immunization: “Consult client’s medical specialist and obtain a written referral regarding the appropriateness of MMR vaccine administration to persons whose immune status may be suppressed as the result of disease or therapy.”

Page 53 (Adacel™):
- Expanded eligibility for Adacel™ for children and adolescents from ≥ 7 years to ≤ 18 years of age.
- A minimum of 2 years is now recommended between the receipt of a previous booster dose of a tetanus/diphtheria –containing vaccine and the administration of Adacel™.

Page 57 (Tuberculin Skin Test - Tubersol®):
- Tuberculin testing that is “recommended and provided free” has been clarified, as are the categories of testing that are not publicly-funded.

Pages 58, 59, 60, and 61 (Typhoid vaccines):
- Amended footnotes to include ViVAXIM™ in the list of interchangeable typhoid vaccines.

Page 59a [Typhoid Vaccine (Combined Purified Vi Polysaccharide Typhoid and Inactivated Hepatitis A Vaccine (ViVAXIM™)):
- New page

Page 67 Yellow Fever Vaccine:
- Under “Contraindications”, wording now consistent with guideline in Section III – Contraindications and Routine Precautions for Immunization: “Consult client’s medical specialist and obtain a written referral regarding the appropriateness of Yellow Fever vaccine administration to persons whose immune status may be suppressed as the result of disease or therapy.”
Please remove and destroy the following pages from Communicable Disease Control Manual, Chapter 2 – Immunization Program:

Section VII – Biological Products
Table of Contents Dated August 2005
Pages 4 and 20 Dated November 2002
Page 4a Dated December 2003
Pages 7, 8, 9, 9a, and 10 Dated November 2004
Pages 16 and 53 Dated August 2004
Page 18 Dated September 2004
Page 22 Dated June 2004
Pages 24, 25, 59, and 61 Dated August 2003
Page 34 Dated June 2005
Pages 57, 58, and 60 Dated March 2003
Page 67 Dated March 2005

Insert the following pages in the Communicable Disease Control Manual, Chapter 2 - Immunization Program:

Section VII – Biological Products
Table of Contents
Pages 4, 7, 8, 9, 9a, 10, 16, 18, 20, 22, 24, 25, 32b, 34, 53, 57, 58, 59, 60, 61, 67
New Page 59a Dated November 2005

If you have any questions or concerns, please contact Karen Pielak, Nurse Epidemiologist, or Cheryl McIntyre, Associate Nurse Epidemiologist, at telephone (604)660-6061, fax (604)660-0197 or by email at karen.pielak@bccdc.ca or cheryl.mcintyre@bccdc.ca

Sincerely,

David Patrick
Director
Epidemiology Services
BC Centre for Disease Control

DMP/kka